866-997-4948(US-Canada Toll Free)

Risperdal Consta LP-Drug Insights, 2017

Published By :

DelveInsight

Published Date : Jan 2017

Category :

Pharmaceutical

No. of Pages : 35 Pages

DelveInsight Drug Report, Risperdal Consta LP- Drug Insights, 2017 highlights the Risperdal Consta LP marketed details, pipeline status and the Global API Manufacturers along with the location. The DelveInsights report covers the Global Market Assessment of the Risperdal Consta LP covering the total sales estimation and also provides the Risperdal Consta LP sales performance during the historical period and forecast period to 2018. DelveInsights Report also covers the detailed clinical assessment of Risperdal Consta LP, patents information and exclusivity data, route of synthesis, competitive landscape, and generic players. In addition to this, DelveInsights Report provides the SWOT analysis for the Risperdal Consta LP.
Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated drug.
Scope
A review of the Risperdal Consta LP based on information derived from company and industry-specific sources
Coverage of the Marketed data of the Risperdal Consta LP on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification
Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and API Manufactures in China & India for Risperdal Consta LP with location details
Patent Expiry Timeline and Exclusivity Details
Route of Synthesis of the API
Global Forecasted Sales Figure to 2018
Qualitative and quantitative assessment of market space
SWOT Analysis
Reasons to buy
Evaluate the marketing status and exclusivity details of Risperdal Consta LP to exploit opportunities for generic drug development opportunities.
Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Risperdal Consta LP.
API intelligence over Risperdal Consta LP and gaining primary intelligence over Active Ingredients manufacturers across the globe.
Understanding the chemical route of synthesis of Risperdal Consta LP.
Uncovering opportunities in the rapidly growing the US market
Stay ahead of competition by understanding the changing competitive landscape
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of the drugs performance
Obtain sales forecast for currently marketed drug for to 2018


1. DelveInsight Report Introduction
2. Risperdal Consta LP Overview
2.1 Market Competition
2.3 Competitors in Development
3 Global Sales Assessment
3.1 Historical Sales of Risperdal Consta LP
3.2 Forecasted Sales of Risperdal Consta LP
4 Product Description
4.1 Mechanism of Action
4.2 Pharmacodynamic Properties
4.3 Pharmacokinetic Properties
5 Marketed Details
5.1 United States
5.2 Europe
6 Patent Information
6.1 Patent Numbers and Expiry Details
6.2 Patent and Exclusivity Expiry Assessment United States (US)
6.3 Patent Details
7 Route of Synthesis
8 Global API Manufacturers Assessment
8.1 The United States Drug Master File (US DMF)
8.2 The Europe Drug Master File (EUDMF)/Active Substance Master File (ASMF)
8.3 The Active Pharmaceutical Ingredient (API) Manufacturers in China
8.4 The Active Pharmaceutical Ingredient (API) Manufacturers in India
9 Generic Players
10 The Pipeline Coverage
11 Clinical Trials Information
11.1 Clinical Trials by Zone
12 Company Profile
12.1 Company Summary
12.2 Company Financials
13 SWOT Analysis
14 References
15 Appendix
16 Methodology
17 Consulting Services
18 About DelveInsight
19 Contact Us
20 Disclaimer

List of Table


Table 1: Risperdal Consta LP, Historical Global Sales (in million USD), 2017
Table 2: Risperdal Consta LP, Forecasted Global Sales (in million USD), 2017
Table 3: Risperdal Consta LP, Description
Table 4: Risperdal Consta LP, Marketed Details the United States (US)
Table 5: Risperdal Consta LP, Marketed Details the Europe (EU)
Table 6: Risperdal Consta LP, Patent/Exclusivity Expiry (Year), 2017
Table 7: Risperdal Consta LP, Patent Number Specific Patent Expiry (Year), 2017
Table 8: Risperdal Consta LP, Patent Details
Table 9: Risperdal Consta LP, Route of Synthesis
Table 10: Risperdal Consta LP, the United States Drug Master File (US DMF), 2017
Table 11: Risperdal Consta LP, the Europe Active Substance Master File (ASMF), 2017
Table 12: Risperdal Consta LP, the API Manufacturers, China, 2017
Table 13: Risperdal Consta LP, the API Manufacturers, India, 2017
Table 14: Risperdal Consta LP, Generic Players, 2017
Table 15: Risperdal Consta LP, Pipeline Drug Details, 2017
Table 16: Risperdal Consta LP, Clinical Trials, 2017
Table 17: Risperdal Consta LP, Clinical Trials by Zone, 2017
Table 18: Company Overview, 2017
Table 19: Risperdal Consta LP, SWOT Analysis, 2017

List of Chart


Figure 1: Risperdal Consta LP, Historical Global Sales (in million USD), 2017
Figure 2: Risperdal Consta LP, Forecasted Global Sales (in million USD), 2017
Figure 3: Risperdal Consta LP, Patent/Exclusivity Expiry (Year), 2017
Figure 4: Risperdal Consta LP, Patent Number Specific Patent Expiry (Year), 2017
Figure 5: Risperdal Consta LP, Route of synthesis
Figure 6: Risperdal Consta LP, the API Manufacturers by the US DMF Status (%), 2017
Figure 7: Risperdal Consta LP, the API Manufacturers by Region, 2017
Figure 8: Risperdal Consta LP, the API Manufacturers by Location/Countries, 2017
Figure 9: Risperdal Consta LP, Generic Players, 2017
Figure 10: Risperdal Consta LP, Clinical Trials by Zone (%), 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *